COST-UTILITY ANALYSIS OF ADALIMUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN PATIENTS IN SPAIN

被引：0
|
作者：
Wang, S. [1 ]
Yang, H. [2 ]
Yang, M. [2 ]
Bao, Y. [1 ]
机构：
[1] AbbVie Inc, N Chicago, IL USA
[2] Anal Grp Inc, Boston, MA USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2452
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY68
引用
收藏
页码：A670 / A670
页数：1
相关论文
共 50 条
  • [11] Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Van Assche, Gert A.
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert R.
    Wolf, Douglas C.
    Kron, Martina
    Tighe, Mary Beth
    Lazar, Andreas
    Thakkar, Roopal
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S123 - S124
  • [12] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Warner, Ben
    Harris, Adam W.
    [J]. GASTROENTEROLOGY, 2012, 143 (01) : E42 - E42
  • [13] Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis
    Sandborn, William
    Van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas
    Kron, Martina
    Tighe, Mary
    Lazar, Andreas
    Thakkar, Roopal
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S3 - S4
  • [14] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY
    Sands, Bruce E.
    Schreiber, Stefan
    Lirio, Richard A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 93 - 94
  • [15] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas C.
    Kron, Martina
    Tighe, Mary Beth
    Lazar, Andreas
    Thakkar, Roopal B.
    [J]. GASTROENTEROLOGY, 2012, 142 (02) : 257 - +
  • [16] Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Montoiro-Allue, Raquel
    Lopez-Del Val, Alejandro
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (03) : 321 - 329
  • [17] Biologics for the treatment of moderate-to-severe ulcerative colitis in pediatric patients
    Albenberg, Lindsey G.
    Mamula, Petar
    Kelsen, Judith R.
    [J]. PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 51 - 58
  • [18] COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN
    Taxonera, C.
    de Andres-Nogales, F.
    Garcia, S.
    Sanchez-Guerrero, A.
    Menchen, B.
    Peral, C.
    Cabez, A.
    Gomez, S.
    Lopez, A.
    Casado, M. A.
    Menchen, L.
    [J]. VALUE IN HEALTH, 2019, 22 : S619 - S619
  • [19] Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
    Taxonera, Carlos
    de Andres-Nogales, Fernando
    Garcia-Lopez, Santiago
    Sanchez-Guerrero, Amelia
    Menchen, Belen
    Peral, Carmen
    Cabez, Ana
    Gomez, Susana
    Lopez-Ibanez de Aldecoa, Alejandra
    Casado, Miguel Angel
    Menchen, Luis
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 73 - 83
  • [20] Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Lopez-Del Val, Alejandro
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 355 - 360
12345